Bisphosphonates in children with hypercalciuria and reduced bone mineral density

Michael Freundlich, Uri S. Alon

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Previous studies have demonstrated reduced bone mineral density (BMD) and biochemical changes of excessive bone resorption in some patients with idiopathic hypercalciuria (IH). Consequently, bisphosphonates have been successfully employed in research animals and adults with IH and reduced BMD. We evaluated the effect of treatment with bisphosphonates in seven patients ages 10-16 years with persistent IH and reduced BMD. In five children, preceding traditional therapy failed. All children received oral alendronate and one also IV Zoledronic acid for 6-18 (median 9.0, mean 10.7) months. With treatment, BMD Z scores in the lumbar spine improved from -2.0 ± 0.3 to -0.8 ± 0.8 (p = 0.002) and in the femoral neck from -1.8 ± 0.4 to -0.7 ± 0.9 (p = 0.01); urine N-telopeptides/creatinine decreased from 372 ± 289 to 72 ± 39 nmol/mmol (p = 0.05) and calcium/ creatinine from 0.29 ± 0.12 to 0.13 ± 0.06 mg/mg (p = 0.009). Height Z scores, normal at baseline in all, remained unaffected, and no new stones or fractures were documented throughout the treatment period. Serum creatinine, electrolytes, calcium, phosphorus and parathyroid hormone remained normal as well. In summary, in children with IH and decreased BMD, treatment with bisphosphonates normalized urine calcium excretion, eliminated urinary symptoms, and significantly improved reduced BMD. These short-term beneficial effects indicate the need for larger prospective studies on the potential of bisphosphonates to serve as a new tool in treating children with IH and reduced BMD.

Original languageEnglish
Pages (from-to)2215-2220
Number of pages6
JournalPediatric Nephrology
Volume23
Issue number12
DOIs
StatePublished - Aug 18 2008

Fingerprint

Hypercalciuria
Diphosphonates
Bone Density
Creatinine
zoledronic acid
Calcium
Urine
Therapeutics
Alendronate
Femur Neck
Bone Resorption
Parathyroid Hormone
Phosphorus
Electrolytes
Spine
Prospective Studies
Serum

Keywords

  • Bisphosphonates
  • Bone mineral density
  • Bone resorption
  • Calciuria
  • Osteopenia

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Bisphosphonates in children with hypercalciuria and reduced bone mineral density. / Freundlich, Michael; Alon, Uri S.

In: Pediatric Nephrology, Vol. 23, No. 12, 18.08.2008, p. 2215-2220.

Research output: Contribution to journalArticle

@article{c734c06d8d81481c9320dc8dec0815a3,
title = "Bisphosphonates in children with hypercalciuria and reduced bone mineral density",
abstract = "Previous studies have demonstrated reduced bone mineral density (BMD) and biochemical changes of excessive bone resorption in some patients with idiopathic hypercalciuria (IH). Consequently, bisphosphonates have been successfully employed in research animals and adults with IH and reduced BMD. We evaluated the effect of treatment with bisphosphonates in seven patients ages 10-16 years with persistent IH and reduced BMD. In five children, preceding traditional therapy failed. All children received oral alendronate and one also IV Zoledronic acid for 6-18 (median 9.0, mean 10.7) months. With treatment, BMD Z scores in the lumbar spine improved from -2.0 ± 0.3 to -0.8 ± 0.8 (p = 0.002) and in the femoral neck from -1.8 ± 0.4 to -0.7 ± 0.9 (p = 0.01); urine N-telopeptides/creatinine decreased from 372 ± 289 to 72 ± 39 nmol/mmol (p = 0.05) and calcium/ creatinine from 0.29 ± 0.12 to 0.13 ± 0.06 mg/mg (p = 0.009). Height Z scores, normal at baseline in all, remained unaffected, and no new stones or fractures were documented throughout the treatment period. Serum creatinine, electrolytes, calcium, phosphorus and parathyroid hormone remained normal as well. In summary, in children with IH and decreased BMD, treatment with bisphosphonates normalized urine calcium excretion, eliminated urinary symptoms, and significantly improved reduced BMD. These short-term beneficial effects indicate the need for larger prospective studies on the potential of bisphosphonates to serve as a new tool in treating children with IH and reduced BMD.",
keywords = "Bisphosphonates, Bone mineral density, Bone resorption, Calciuria, Osteopenia",
author = "Michael Freundlich and Alon, {Uri S.}",
year = "2008",
month = "8",
day = "18",
doi = "10.1007/s00467-008-0940-9",
language = "English",
volume = "23",
pages = "2215--2220",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Bisphosphonates in children with hypercalciuria and reduced bone mineral density

AU - Freundlich, Michael

AU - Alon, Uri S.

PY - 2008/8/18

Y1 - 2008/8/18

N2 - Previous studies have demonstrated reduced bone mineral density (BMD) and biochemical changes of excessive bone resorption in some patients with idiopathic hypercalciuria (IH). Consequently, bisphosphonates have been successfully employed in research animals and adults with IH and reduced BMD. We evaluated the effect of treatment with bisphosphonates in seven patients ages 10-16 years with persistent IH and reduced BMD. In five children, preceding traditional therapy failed. All children received oral alendronate and one also IV Zoledronic acid for 6-18 (median 9.0, mean 10.7) months. With treatment, BMD Z scores in the lumbar spine improved from -2.0 ± 0.3 to -0.8 ± 0.8 (p = 0.002) and in the femoral neck from -1.8 ± 0.4 to -0.7 ± 0.9 (p = 0.01); urine N-telopeptides/creatinine decreased from 372 ± 289 to 72 ± 39 nmol/mmol (p = 0.05) and calcium/ creatinine from 0.29 ± 0.12 to 0.13 ± 0.06 mg/mg (p = 0.009). Height Z scores, normal at baseline in all, remained unaffected, and no new stones or fractures were documented throughout the treatment period. Serum creatinine, electrolytes, calcium, phosphorus and parathyroid hormone remained normal as well. In summary, in children with IH and decreased BMD, treatment with bisphosphonates normalized urine calcium excretion, eliminated urinary symptoms, and significantly improved reduced BMD. These short-term beneficial effects indicate the need for larger prospective studies on the potential of bisphosphonates to serve as a new tool in treating children with IH and reduced BMD.

AB - Previous studies have demonstrated reduced bone mineral density (BMD) and biochemical changes of excessive bone resorption in some patients with idiopathic hypercalciuria (IH). Consequently, bisphosphonates have been successfully employed in research animals and adults with IH and reduced BMD. We evaluated the effect of treatment with bisphosphonates in seven patients ages 10-16 years with persistent IH and reduced BMD. In five children, preceding traditional therapy failed. All children received oral alendronate and one also IV Zoledronic acid for 6-18 (median 9.0, mean 10.7) months. With treatment, BMD Z scores in the lumbar spine improved from -2.0 ± 0.3 to -0.8 ± 0.8 (p = 0.002) and in the femoral neck from -1.8 ± 0.4 to -0.7 ± 0.9 (p = 0.01); urine N-telopeptides/creatinine decreased from 372 ± 289 to 72 ± 39 nmol/mmol (p = 0.05) and calcium/ creatinine from 0.29 ± 0.12 to 0.13 ± 0.06 mg/mg (p = 0.009). Height Z scores, normal at baseline in all, remained unaffected, and no new stones or fractures were documented throughout the treatment period. Serum creatinine, electrolytes, calcium, phosphorus and parathyroid hormone remained normal as well. In summary, in children with IH and decreased BMD, treatment with bisphosphonates normalized urine calcium excretion, eliminated urinary symptoms, and significantly improved reduced BMD. These short-term beneficial effects indicate the need for larger prospective studies on the potential of bisphosphonates to serve as a new tool in treating children with IH and reduced BMD.

KW - Bisphosphonates

KW - Bone mineral density

KW - Bone resorption

KW - Calciuria

KW - Osteopenia

UR - http://www.scopus.com/inward/record.url?scp=55649101858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649101858&partnerID=8YFLogxK

U2 - 10.1007/s00467-008-0940-9

DO - 10.1007/s00467-008-0940-9

M3 - Article

VL - 23

SP - 2215

EP - 2220

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 12

ER -